Fassett William E
Department of Pharmacotherapy, College of Pharmacy, Washington State University-Spokane, PO Box 1495, Spokane, WA 99210-1495, USA.
Ann Pharmacother. 2006 May;40(5):917-24. doi: 10.1345/aph.1G485. Epub 2006 Apr 25.
To review Public Law (PL) 109-41-the Patient Safety and Quality Improvement Act of 2005 (PSQIA)-and summarize key medication error research that contributed to congressional recognition of the need for this legislation.
Relevant publications related to medication error research, patient safety programs, and the legislative history of and commentary on PL 109-41, published in English, were identified by MEDLINE, PREMEDLINE, Thomas (Library of Congress), and Internet search engine-assisted searches using the terms healthcare quality, medication error, patient safety, PL 109-41, and quality improvement. Additional citations were identified from references cited in related publications.
All relevant publications were reviewed. Summarization of the PSQIA was carried out by legal textual analysis.
PL 109-41 provides privilege and confidentiality for patient safety work product (PSWP) developed for reporting to patient safety organizations (PSOs). It does not establish federal mandatory reporting of significant errors; rather, it relies on existing state reporting systems. The Act does not preempt stronger state protections for PSWP. The Agency for Healthcare Research and Quality is directed to certify PSOs and promote the establishment of a national network of patient safety databases. Whistleblower protection and penalties for unauthorized disclosure of PSWP are among its enforcement mechanisms.
The Act protects clinicians who report minor errors to PSOs and protects the information from disclosure, but providers must increasingly embrace a culture of interdisciplinary concern for patient safety if this protection is to have real impact on patient care.
回顾公法(PL)109 - 41——《2005年患者安全与质量改进法案》(PSQIA),并总结关键的用药错误研究,这些研究促使国会认识到有必要制定这项立法。
通过MEDLINE、PREMEDLINE、托马斯(国会图书馆)以及使用医疗质量、用药错误、患者安全、PL 109 - 41和质量改进等术语的互联网搜索引擎辅助搜索,识别出以英文发表的与用药错误研究、患者安全计划以及PL 109 - 41的立法历史和评论相关的相关出版物。从相关出版物中引用的参考文献中识别出其他引文。
对所有相关出版物进行了审查。通过法律文本分析对PSQIA进行了总结。
PL 109 - 41为向患者安全组织(PSO)报告而开发的患者安全工作成果(PSWP)提供特权和保密。它没有规定联邦对重大错误的强制报告;相反,它依赖现有的州报告系统。该法案并不优先于对PSWP更强的州保护。医疗保健研究与质量局被指示对PSO进行认证,并促进建立全国患者安全数据库网络。举报人保护以及对未经授权披露PSWP的处罚是其执法机制之一。
该法案保护向PSO报告轻微错误的临床医生,并保护信息不被披露,但如果这种保护要对患者护理产生实际影响,提供者必须越来越多地接受一种跨学科关注患者安全的文化。